{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-25-001328","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.551111+00:00","generated_at":"2026-05-17T13:53:00.789900+00:00","sec_items":["1.01","2.02","3.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vivani Medical raises $10M, reports Q2 loss of $7.1M, advances semaglutide implant NPM-139","bullets":["Raised $10M via private placement of 7.94M shares at $1.26/share with director-affiliated entity.","Q2 2025 net loss $7.1M vs $5.3M in Q2 2024; cash $8.1M as of June 30, 2025.","Positive preclinical data for NPM-139: ~20% weight loss maintained >6 months with single implant.","Plans to initiate NPM-139 clinical program in 2026; spin off Cortigent division in H2 2025.","Appointed Anthony Baldor as CFO; additional $21.25M committed capital through July 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-25-001328","json":"https://secwatch.observer/filing/0001753926-25-001328.json","markdown":"https://secwatch.observer/filing/0001753926-25-001328.md","text":"https://secwatch.observer/filing/0001753926-25-001328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392625001328/0001753926-25-001328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392625001328/vani-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:53:00.789900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}